SCHEMBL12486332

SCHEMBL12486332

Cc1ccc(CN2C(=O)c3ccccc3C2=O)n1C

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PABPC1 P11940 1/20 0.51
ALOX15 P16050 1/20 0.51
MAPK1 P28482 1/20 0.51
MAPT P10636 2/20 0.45
RECQL P46063 1/20 0.45
CASP3 P42574 2/20 0.45
GLS O94925 1/20 0.44
HPGD P15428 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 1/20 0.44
PKM P14618 1/20 0.44
KMT2A Q03164 1/20 0.44
NPC1 O15118 1/20 0.43
TSHR P16473 1/20 0.43
RAB9A P51151 1/20 0.43
RPS6KA2 Q15349 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10666590 0.77 HRH1 (0.49) PABPC1ALOX15MAPK1MAPT
SCHEMBL10672687 0.75 CA12 (0.57) ALOX15MAPTCASP3HPGDALDH1A1
SCHEMBL10672436 0.75 MAPT (0.43) PABPC1ALOX15MAPK1MAPTRECQL
SCHEMBL2173361 0.74 POLB (0.46) MAPK1MAPTNPSR1ALDH1A1MEN1
SCHEMBL10666833 0.74 CA12 (0.44) ALOX15MAPTALDH1A1MEN1KMT2A
SCHEMBL10665212 0.73 KDM4E (0.48) PABPC1ALOX15MAPK1HPGDALDH1A1
SCHEMBL10672699 0.73 CASP3 (0.40) PABPC1ALOX15MAPK1MAPTRECQL
SCHEMBL10668747 0.72 KDM4E (0.48) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL29820192 0.71 CASP3 (0.65) PABPC1ALOX15MAPK1MAPTCASP3
SCHEMBL8737445 0.71 CASP3 (0.65) PABPC1ALOX15MAPK1MAPTCASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973078-B2 Sulfonamide compound or salt thereof ASTELLAS PHARMA INC. (JP) 2011-07-05 US disclosed
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF PTGER1, CYSLTR1, PTGER2 PABPC1 3843/4885ALOX15 209/4885MAPK1 295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.